Recipharm Annual Report 2006

More documents

Recommendations

Info

DISCLOSURES FOR INDIVIDUAL ITEMS Note 1 Purchases and sales within the Group and related party transactions PARENT COMPANY 2006 2005 Sales to Group companies 26,656,663 32,673,078 Purchases from Group companies 91,262,325 36,523,341 The Group rents factory and office premises in Haninge from KB Titania, which is an associated company. The annual fee for 2006 amounts to MSEK 11. Note 2 Operating leases GROUP 2006 2005 Leasing charges for the financial year 956,181 0 Estimated fees, 2007 346,00 0 Estimated fees, 2008 0 0 Estimated fees, 2009 0 0 Estimated fees, 2010 0 0 Estimated fees, 2011 0 0 Operating leases PARENT COMPANY 2006 2005 Leasing charges for the financial year 6,320,834 0 Estimated fees, 2007 5,316,660 5,286,660 Estimated fees, 2008 0 1,762,220 Estimated fees, 2009 0 0 Estimated fees, 2010 0 0 Estimated fees, 2011 0 0 Financial leases GROUP 2006 2005 Leasing charges for the financial year 2,242,601 0 Estimated fees, 2007 2,017,994 1,842,887 Estimated fees, 2008 1,842,887 1,831,668 Estimated fees, 2009 1,831,668 1,831,668 Estimated fees, 2010 1,831,668 1,831,668 Estimated fees, 2011 1,831,668 0
Note 3 Fees and remuneration for audit GROUP 2006 2005 Ernst & Young AB 1,420,092 562,460 Audit assignment 90,000 118,000 Other assignments 1,510,092 680,460 PARENT COMPANY 2006 2005 Ersnt & Young AB 1,430,092 300,000 Audit assignment 90,000 118,000 Other assignments 1,520,092 418,000 Note 4 Personnel Average number of employees The average number of employees is based on attendance hours, paid by the Company, in relation to standard working hours. GROUP 2006 2005 Average number of employees 570 572 of whom women 342 354 PARENT COMPANY 2006 2005 Average number of employees 85 82 of whom women 52 49 Absence due to illness Absence due to illness as a percentage of standard working hours GROUP Number of employees Absence due to illness, % Of which >60 days, % Year, Age Men Women Men Women Men Women 2006, < 29 30 17 4.8 10.9 14.1 50.1 2005, < 29 29 30 5.7 15.5 17.5 77.4 2006, 30-49 128 205 3.7 7.2 35.2 48.1 2005, 30-49 121 190 3.7 21.6 42.2 2006, > 50 70 120 4.8 8.4 55.5 68.3 2005, > 50 68 134 5.4 92.5 82.2 Total, 2006 228 342 4.2 7.8 39.2 55.7 Total, 2005 218 354 4.5 8.6 46.7 64.0
Page 1 and 2: ANNUAL REPORT AND CONSOLIDATED ACCO
Page 3 and 4: the form of powders and granulates,
Page 5 and 6: Research and development Recip’s
Page 7 and 8: Investments Gross investments for t
Page 9 and 10: CONSOLIDATED BALANCE SHEETS ASSETS
Page 11 and 12: CONSOLIDATED CASH FLOW STATEMENTS 1
Page 13 and 14: PARENT COMPANY BALANCE SHEETS ASSET
Page 15 and 16: PARENT COMPANY CASH FLOW ANALYSES O
Page 17: Depreciation/amortisation principle
Page 21 and 22: The Norwegian branch stands for SEK
Page 23 and 24: PARENT COMPANY 31 Dec 2006 31 Dec 2
Page 25 and 26: Acquisition value via transfer of a
Page 27 and 28: Closing accumulated acquisition cos
Page 29 and 30: Repayments of borrowings within 5 y
Page 31 and 32: Stockholm, 22 March 2007 Anders G C

Recipharm Annual Report 2006

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?